{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T16:36:14Z","timestamp":1776702974087,"version":"3.51.2"},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2014,7,21]],"date-time":"2014-07-21T00:00:00Z","timestamp":1405900800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0102577","type":"journal-article","created":{"date-parts":[[2014,7,22]],"date-time":"2014-07-22T04:46:58Z","timestamp":1406004418000},"page":"e102577","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":27,"title":["A Peptide of Heparin Cofactor II Inhibits Endotoxin-Mediated Shock and Invasive Pseudomonas aeruginosa Infection"],"prefix":"10.1371","volume":"9","author":[{"given":"Martina","family":"Kalle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praveen","family":"Papareddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gopinath","family":"Kasetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariena J. A.","family":"van der Plas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"M\u00f6rgelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Malmsten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur","family":"Schmidtchen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,7,21]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0924-8579(10)70003-0","article-title":"The continuing crisis in antibiotic resistance","volume":"36","author":"GL French","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1469-0691.2008.02126.x","article-title":"Antimicrobial resistance in Europe and its potential impact on empirical therapy","volume":"14","author":"GM Rossolini","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMra1208623","article-title":"Severe sepsis and septic shock","volume":"369","author":"DC Angus","year":"2013","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1001\/jama.2009.1754","article-title":"International study of the prevalence and outcomes of infection in intensive care units","volume":"302","author":"JL Vincent","year":"2009","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/01.CCM.0000194725.48928.3A","article-title":"Sepsis in European intensive care units: results of the SOAP study","volume":"34","author":"JL Vincent","year":"2006","journal-title":"Crit Care Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1056\/NEJMoa022139","article-title":"The epidemiology of sepsis in the United States from 1979 through 2000","volume":"348","author":"GS Martin","year":"2003","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"6303","DOI":"10.4049\/jimmunol.1203030","article-title":"Proteolytic activation transforms heparin cofactor II into a host defense molecule","volume":"190","author":"M Kalle","year":"2013","journal-title":"J Immunol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1097\/CCM.0b013e3181c98d21","article-title":"Inflammation and coagulation","volume":"38","author":"M Levi","year":"2010","journal-title":"Crit Care Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/01.CCM.0000194731.08896.99","article-title":"High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety","volume":"34","author":"CJ Wiedermann","year":"2006","journal-title":"Crit Care Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.290.2.238","article-title":"Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial","volume":"290","author":"E Abraham","year":"2003","journal-title":"JAMA"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"R36","DOI":"10.1186\/cc7747","article-title":"A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia","volume":"13","author":"PF Laterre","year":"2009","journal-title":"Crit Care"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1538-7836.2010.04089.x","article-title":"Recombinant human tissue factor pathway inhibitor exerts anticoagulant, anti-inflammatory and antimicrobial effects in murine pneumococcal pneumonia","volume":"9","author":"FE Van Den Boogaard","year":"2011","journal-title":"J Thromb Haemost"},{"key":"ref13","first-page":"CD004388","article-title":"Human recombinant activated protein C for severe sepsis","volume":"3","author":"AJ Marti-Carvajal","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1097\/00003246-200111000-00007","article-title":"Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study","volume":"29","author":"E Abraham","year":"2001","journal-title":"Crit Care Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/nbt1267","article-title":"Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies","volume":"24","author":"RE Hancock","year":"2006","journal-title":"Nat Biotechnol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nbt.2572","article-title":"Antimicrobial peptides stage a comeback","volume":"31","author":"JL Fox","year":"2013","journal-title":"Nat Biotechnol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3109\/07388551.2011.594423","article-title":"Antimicrobial peptides: key components of the innate immune system","volume":"32","author":"M Pasupuleti","year":"2012","journal-title":"Crit Rev Biotechnol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.it.2008.12.003","article-title":"AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense","volume":"30","author":"Y Lai","year":"2009","journal-title":"Trends Immunol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/0968051907088275","article-title":"Human antimicrobial proteins effectors of innate immunity","volume":"13","author":"J Harder","year":"2007","journal-title":"J Endotoxin Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/415389a","article-title":"Antimicrobial peptides of multicellular organisms","volume":"415","author":"M Zasloff","year":"2002","journal-title":"Nature"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/1097-0282(2000)55:1<4::AID-BIP30>3.0.CO;2-M","article-title":"Amphipathic, alpha-helical antimicrobial peptides","volume":"55","author":"A Tossi","year":"2000","journal-title":"Biopolymers"},{"key":"ref22","first-page":"27","article-title":"Immunomodulatory properties of defensins and cathelicidins","volume":"306","author":"DM Bowdish","year":"2006","journal-title":"Curr Top Microbiol Immunol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.4049\/jimmunol.0901813","article-title":"Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment","volume":"184","author":"A Nijnik","year":"2010","journal-title":"J Immunol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"e51313","DOI":"10.1371\/journal.pone.0051313","article-title":"Host defense peptides of thrombin modulate inflammation and coagulation in endotoxin-mediated shock and Pseudomonas aeruginosa sepsis","volume":"7","author":"M Kalle","year":"2012","journal-title":"PLoS One"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.bbamem.2014.01.026","article-title":"An antimicrobial helix A-derived peptide of heparin cofactor II blocks endotoxin responses in vivo","volume":"1838","author":"P Papareddy","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/j.bbamem.2013.06.015","article-title":"Importance of lipopolysaccharide aggregate disruption for the anti-endotoxic effects of heparin cofactor II peptides","volume":"1828","author":"S Singh","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cellimm.2012.11.009","article-title":"A comprehensive summary of LL-37, the factotum human cathelicidin peptide","volume":"280","author":"D Vandamme","year":"2012","journal-title":"Cell Immunol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"e1000857","DOI":"10.1371\/journal.ppat.1000857","article-title":"Proteolysis of human thrombin generates novel host defense peptides","volume":"6","author":"P Papareddy","year":"2010","journal-title":"PLoS Pathog"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.4049\/jimmunol.176.4.2455","article-title":"Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37","volume":"176","author":"N Mookherjee","year":"2006","journal-title":"J Immunol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0022-1759(91)90021-7","article-title":"Ultrasensitive assays for endogenous antimicrobial polypeptides","volume":"137","author":"RI Lehrer","year":"1991","journal-title":"J Immunol Methods"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"28387","DOI":"10.1074\/jbc.M110.127019","article-title":"C-terminal peptides of tissue factor pathway inhibitor are novel host defense molecules","volume":"285","author":"P Papareddy","year":"2010","journal-title":"J Biol Chem"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nprot.2007.521","article-title":"Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances","volume":"3","author":"I Wiegand","year":"2008","journal-title":"Nat Protoc"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/j.1600-0625.2011.01391.x","article-title":"Thymic stromal lymphopoietin exerts antimicrobial activities","volume":"20","author":"A Sonesson","year":"2011","journal-title":"Exp Dermatol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1159\/000327016","article-title":"The C-terminal sequence of several human serine proteases encodes host defense functions","volume":"3","author":"G Kasetty","year":"2011","journal-title":"J Innate Immun"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"9057","DOI":"10.1021\/bi800991e","article-title":"Rational design of antimicrobial C3a analogues with enhanced effects against Staphylococci using an integrated structure and function-based approach","volume":"47","author":"M Pasupuleti","year":"2008","journal-title":"Biochemistry"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/jac\/dkn074","article-title":"Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections","volume":"61","author":"TR Fritsche","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.smim.2003.10.003","article-title":"TLR signaling pathways","volume":"16","author":"K Takeda","year":"2004","journal-title":"Semin Immunol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ijmm.2007.04.001","article-title":"Structural biology of the LPS recognition","volume":"297","author":"R Jerala","year":"2007","journal-title":"Int J Med Microbiol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1128\/AAC.01515-10","article-title":"Structure-activity studies and therapeutic potential of host defense peptides of human thrombin","volume":"55","author":"G Kasetty","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1146\/annurev.iy.11.040193.000541","article-title":"Defensins: antimicrobial and cytotoxic peptides of mammalian cells","volume":"11","author":"RI Lehrer","year":"1993","journal-title":"Annu Rev Immunol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00134-012-2769-8","article-title":"Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012","volume":"39","author":"RP Dellinger","year":"2013","journal-title":"Intensive Care Med"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1056\/NEJM199908193410807","article-title":"Disseminated intravascular coagulation","volume":"341","author":"M Levi","year":"1999","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1055\/s-0037-1615899","article-title":"Disseminated intravascular coagulation","volume":"82","author":"M Levi","year":"1999","journal-title":"Thromb Haemost"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/cc11220","article-title":"Antimicrobial peptides and their potential application in inflammation and sepsis","volume":"16","author":"T Schuerholz","year":"2012","journal-title":"Crit Care"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1189\/jlb.0704380","article-title":"Impact of LL-37 on anti-infective immunity","volume":"77","author":"DM Bowdish","year":"2005","journal-title":"J Leukoc Biol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm0398-298","article-title":"Activation of the contact-phase system on bacterial surfaces\u2014a clue to serious complications in infectious diseases","volume":"4","author":"H Herwald","year":"1998","journal-title":"Nat Med"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00109-009-0564-y","article-title":"Contact system activation in severe infectious diseases","volume":"88","author":"S Oehmcke","year":"2010","journal-title":"J Mol Med (Berl)"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/01.CCM.0000153520.31562.48","article-title":"Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure","volume":"33","author":"JF Dhainaut","year":"2005","journal-title":"Crit Care Med"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ejphar.2007.06.027","article-title":"Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model","volume":"571","author":"T Sha","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"R49","DOI":"10.1186\/cc5783","article-title":"Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis","volume":"11","author":"FA Bozza","year":"2007","journal-title":"Crit Care"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1159\/000316286","article-title":"The systemic pro-inflammatory response in sepsis","volume":"2","author":"HK de Jong","year":"2010","journal-title":"J Innate Immun"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/10408363.2013.764490","article-title":"Biomarkers of sepsis","volume":"50","author":"JD Faix","year":"2013","journal-title":"Crit Rev Clin Lab Sci"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/bjs.1800810914","article-title":"Interleukin 6 is a prognostic indicator of outcome in severe intra-abdominal sepsis","volume":"81","author":"RT Patel","year":"1994","journal-title":"Br J Surg"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2796.2007.01821.x","article-title":"Role of the innate immune system in host defence against bacterial infections: focus on the Toll-like receptors","volume":"261","author":"B Albiger","year":"2007","journal-title":"J Intern Med"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0102577","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T23:25:52Z","timestamp":1588980352000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0102577"}},"subtitle":[],"editor":[{"given":"Patricia T.","family":"Bozza","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,7,21]]},"references-count":54,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,7,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0102577","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,21]]}}}